In-Person CME Webcast
1.00 CME/CE Credit
Memory Loss, Alzheimer’s Disease, & Dementia - Update 2026
This session covers the diagnosis and management of Alzheimer's disease and other common dementias, including Lewy body dementia and LATE. Learners will review NIA-AA criteria, when to order biomarkers including new plasma markers, emerging disease-modifying therapies lecanemab and donanemab, and practical approaches to driving, agitation, diet, and exercise
CME/CE Information
1.00 AMA PRA Category 1 Credits™ or 1.00 AANP, including 0.20 AANP Pharm
Release Date: 10/9/2026
Expiration Date: 11/29/2026
Faculty
Learning Objectives
- Apply the NIA-AA Criteria to diagnosis Alzheimer’s disease dementia (AD) and mild cognitive impairment (MCI) due to AD
- Explain the role of biomarkers, including new plasma markers, in the diagnosis of AD and other common dementias, including dementia with Lewy bodies
- Discuss LATE (Limbic-predominant, Age-related, TDP-43 Encephalopathy)
- Describe the use of lecanemab (Leqembi) and donanemab (Kisunla) in the management of AD
- Develop strategies to manage agitation and driving safety in patients with dementia, and discuss the data on diet and exercise for memory
Faculty
Andrew E. Budson, MD
Chief of Cognitive Behavioral Neurology, Veterans Affairs Healthcare System, Boston, Massachusetts
Associate Director, Alzheimer’s Disease Research Center, Boston University Medical Center, Boston, MA
Professor of Neurology, Boston University School of Medicine, Boston, MA
Lecturer in Neurology, Harvard Medical School, Boston, MA
Learn MoreDisclosures
The following relevant financial relationships have been disclosed by those in a position to influence the content of this activity. All relevant relationships have been mitigated by Pri-Med Institute:
Andrew Budson, MD: Advisor, Consultant and Speaker for Eli Lilly; and Advisor for AbbVie; Independent Researcher for Eisai, Novo Nordisk and Vox Neuro
Ty Gluckman, MD (Moderator): Consultant for OptumRx
All others in control of content for this activity have disclosed no relevant financial relationships.
CME/CE Information
AMA PRA Category 1 Credits™
Accreditation Statement
Pri-Med Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement
Pri-Med Institute designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AANP
Accreditation Statement
Pri-Med Institute is accredited by the American Association of Nurse Practitioners® as an approved provider of nurse practitioner continuing education. Provider number: 040308.
Designation Statement
This activity is approved for 1.00 contact hour (which includes 0.20 hour of pharmacology).
Fine Print
The preferred browser is Google Chrome. If using a different browser, such as Safari, Firefox or Edge, make sure you are using the most up-to-date version. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection is not required; however, it is recommended for faster download times.
The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, DBC Pri-Med, LLC.
Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.
Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.
Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP.
Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME/CE activities to disclose personal financial relationships with commercial interests or ineligible companies prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to mitigate real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. All relevant financial relationships have been mitigated Financial disclosures for everyone in control of educational content are provided before the start of each CME/CE activity.
Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.
Questions?
If you have questions about this activity, please email support@pri-med.com or call (877) 477-4633.